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Case 
report
Abstract
PET Imaging with [11C]-choline has become a useful tool in 
the investigation of prostate cancer, with as main application 
the assessment of previously treated patients presenting with 
rising PSA and negative conventional imaging procedures. In 
this case report we describe [11C]-choline PET/CT findings in 
a patient with a locally advanced cancer, which could be suc-
cessfully identified thanks to the early image acquisition and 
the delayed urinary excretion of the carbon-11 labeled tracer.
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Herein we report the case of a 75-year-old man affected by 
prostate cancer (Gleason Score 5+4) with elevated serum PSA 
(48.5 ng/ml) at the moment of presentation. The patient was at high 
risk for secondary morbidity following radical intervention, thus he 
underwent luteinizing hormone-releasing hormone (LHRH) agonist 
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therapy, resulting in good PSA control. Serial bone scans during 
follow up were all negative for skeletal metastatic lesions. Six 
years later, routine controls showed rising PSA levels (6.83 ng/ml) 
not responding to maximal androgen blockade (MAB). The refer-
ring clinician required a [11C]-choline PET/CT for patient restaging 
before intensity modulated radiation therapy (IMRT).
PET/CT was performed 10 minutes after IV injection of 360 
MBq of [11C]-choline, on a Siemens Biograph 6 LSO scanner. 
PET images demonstrated an increased [11C]-choline uptake 
in the prostate gland extending to the adjacent tissues. The 
early image acquisition and the delayed urinary excretion of 
[11C]-choline permitted the detection of bladder wall infiltration 
(Figures 1 and 2).
Since its first introduction in 1997 [1], PET Imaging with [11C]-
choline has become a useful tool in the investigation of prostate 
cancer, with its main application in previously treated patients with 
rising PSA serum levels and negative conventional imaging pro-
cedures [2]. Its diagnostic capability is not only limited to loco 
regional lymph nodes and distant bone metastases, but also in 
the detection of local disease [2, 3]. 
However, because of the short half-life of carbon-11 (T1/2 
20 min), requiring on site cyclotron production, the [18F]-labelled 
analogue (18F-fluorocholine) was developed and introduced in 
clinical practice with similar applications [4]. No significant differ-
ences are reported in the two tracer distributions except for an early 
urinary appearance of [18F]-fluorocholine in the urinary tract due 
to an incomplete tubular reabsorption [5]. This excretion does not 
affect the overall diagnostic accuracy of [18F]-choline PET, but can 
be a drawback when considering local recurrence. Compared with 
[18F]-choline, [11C]-choline has a negligible urinary elimination 
which, in selected cases, proves to be an advantage. Nonetheless, 
dedicated protocols to minimize the influence of bladder activity 
can be easily implemented and, whatever the radiopharmaceutical 
used, we recommend obtaining an empty bladder when evaluating 
prostate cancer patients.
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Figure 2. Coronal and sagittal low dose CT (A) and fused PET/CT images (B) showing the full extent of neoplastic disease interesting the prostate 
gland up to the inferior bladder wall.
Figure 1. Axial and MIP images of [11C]-choline PET/CT scan demonstrating bladder wall invasion (dashed arrows) (A), along with persisting 
disease in the prostate gland (straight arrows) (B).
A B MIP image
A B
